HK Stock Market Move | TECHTRONIC IND (00669) falls more than 3%, with some of the company's businesses possibly impacted by restructuring and macroeconomic uncertainty.
Chuang Ke Industrial (00669) fell more than 3%, as of the time of issuance, it fell 2.7% to HK$104.7, with a turnover of HK$176 million.
TECHTRONIC IND (00669) fell more than 3%, dropping 2.7% to 104.7 Hong Kong dollars as of the time of writing, with a turnover of 176 million Hong Kong dollars.
On the news front, a report from Lyon pointed out that TECHTRONIC IND's flagship brands Milwaukee and Ryobi recorded a mid to high single-digit growth, but restructuring and macro uncertainty may still weigh on other businesses. Milwaukee's 15% sales growth comes from data centers, and the company believes that with its leading position in the mechanical, electrical, and plumbing engineering sectors, long-term double-digit growth can be achieved, bringing visible demand in the non-residential end market.
The bank believes that considering the lower-profit business adjustments, TECHTRONIC IND's profit forecasts for 2026 to 2028 have been lowered by 1.1% to 3.4%. However, as the company announced the cancellation of a buyback of 300,000 shares yesterday and plans to repurchase $500 million in the next 18 months, the bank has slightly raised its target price-earnings ratio from 19.5 times to 19.8 times to reflect investor recognition of the buyback amid macro uncertainty.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


